Iron Path Capital (Iron Path), a private equity firm focused on healthcare and specialty industrials, announced the appointment of Jake Fitzgerald as Chief Executive Officer of PureTech Scientific (PureTech), a global leader in glycolic acid synthesis and technology. PureTech was founded by Iron Path after acquiring the Glycolic Acid business from The Chemours Company last August.

Fitzgerald most recently served as President of Americas Packaging at Essentra, where he had been promoted after a five year tenure as Regional Business Director. Prior to Essentra, Fitzgerald was Site Manager at Dow Chemical. His previous experience gives him a wealth of industry knowledge to guide PureTech into the next era of opportunities and success.

"Jake’s keen understanding of market trends and visionary leadership are exactly what PureTech needs to continue its trajectory of success," said Scott Mraz, co-founder and managing partner of Iron Path. "We are confident that under his stewardship, Jake will empower the PureTech team to drive further innovation, create significant value for customers, and exceed our ambitious goals of setting new standards in our field."

Fitzgerald’s appointment underscores Iron Path’s and PureTech’s shared commitment to innovation in the Life Sciences and Specialty Chemical industries. Under his leadership, PureTech is poised to solidify its position as an industry leader, providing ultra-high purity alpha hydroxy acids across the Life Science and Specialty chemical sectors.